ArticleMolecular neurobiology2025
iTBS Improves Behavioral Abnormalities and Synaptic Defects in Fmr1 KO Rats by Regulating the Autophagy Pathway.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Synaptic dysfunction resulting from abnormal autophagy may contribute to the pathogenesis of fragile X syndrome (FXS). Intermittent theta burst stimulation (iTBS) is a novel magnetic stimulation mode that has shown promising therapeutic potential in various neurological disorders. However, the therapeutic effects of iTBS on FXS-related behavior abnormality and its underlying mechanism remain unclear. In this study, we investigated whether iTBS could ameliorate behavioral abnormalities and synaptic dysfunction associated with FXS by modulating the autophagy pathway. This study utilized Fmr1 knockout (KO) rats as experimental models. The rats underwent a 2-week iTBS intervention, and behavioral changes were assessed through a series of behavioral tests. Electrophysiological recordings were performed to examine alterations in hippocampal neural oscillations. Golgi staining and Western blotting were utilized to evaluate changes in synaptic structure and synaptic related proteins, while Western blotting and immunofluorescence were employed to assess alterations in autophagy-related proteins. Our results demonstrated that iTBS significantly improved behavioral deficits in Fmr1 KO rats. Furthermore, iTBS effectively attenuated abnormally heightened hippocampal theta-gamma phase-amplitude coupling in these rats. Treatment with iTBS also led to sustained improvements in synaptic defect, along with the restoration of CaMKK2 activity and autophagy defect in the hippocampus of Fmr1 KO rats. These findings underscored the beneficial effects of iTBS on aberrant behavior and synaptic defects in Fmr1 KO rats, highlighting the involvement of the CaMKK2-dependent autophagy pathway in this process and suggesting the potential therapeutic value of iTBS for individuals with FXS.
Indexed as
Identifiers
41350451What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.